Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (March 2025)
16 slides from Bioventix's investor presentation, Mar 31, 2025
Slide 1: Bioventix plc
1 Bioventix plc 31 March 2025 Bioventix
Slide 2: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 3: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Fertility heart attack & Neurology & Vitamin D Thyroid function Drug testing (testosterone, heart failure Alzheimer’s (25-OH vitamin D) (thyroxine, T3) (THC) estradiol, (troponin, BNPs) (Taus) progesterone) ▪Bioventix has a portfolio of ~30 antibodies that are sold
Slide 4: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year ▪Bioventix takes about 1 year to create new antibodies Prototype test Old test 2-4 years ▪Even for established diagnostics, customers take 2-4 years to prototype tests, = 3-5 years total conduct f
Slide 5: Key Interim Financials
5 Key Interim Financials £ (‘000) year to ½ year to ½ year to Revised Cavendish 30.6.24 31.12.23 31.12.24 forecast 2024/25 Sales 13,610 6,680 6,730 13,500 (+1%) P/(L) before tax 10,600 5,240 5,050 10,300 (-4%) P/(L) after tax 8,100 4,020 3,770 7,900 (-6%) Period-end cash 6,000 5,510 5,140 5,200 Spri
Slide 6: Key Financials: Notes
6 Key Financials: Notes ▪ Vitamin D and core antibodies: sales were level with the previous reporting period as expected for antibodies that feature in mature diagnostic products ▪ Other core historic antibodies: sales were similarly steady ▪ Troponin: sales were also similar. The new prognostic app
Slide 7: Bioventix
7 ▪This data relates to the last complete financial year 2023/24 but are reflective of sales for the period except for Taus/neuro where sales have increased ▪Siemens troponin revenues will terminate in June 2032 Bioventix
Slide 8: Alzheimer's Disease biomarkers and imaging
8 (A) Tau PET (T) (T) (N) ▪Alzheimer’s is complex and is ▪The disease progresses many different amongst individuals years before symptoms appear ▪Changes at a cell level include ▪Neurodegeneration in the Amyloid PET (A) Amyloid plaques outside neurons brain is clear in later disease and Tau tangles
Slide 9: Prototype Blood-based Assays and Antibodies
9 Prototype Blood-based Assays and Antibodies (in a rapidly evolving field) (A) Tau.NT Tau.MTBR [research phase] Detector/sandwich partner Tau tangles? (T) (T) Tau Brain-derived Tau [B-D Tau] Phospho Tau 217 [pT217] Neurodegeneration (N) Amyloid plaques (A) (N) ▪Three SMAs (two B-D Tau and one detec
Slide 10: Other Pipeline Developments
10 Other Pipeline Developments ▪ Amyloid (Pre-Diagnostics/Alzheimer’s): ARIA is an important side-effect of new anti-amyloid drugs for Alzheimer’s. Pre-Diagnostics assays relate to amyloid metabolism and could help screen for ARIA vulnerable patients, before or during treatment ▪ Industrial biomonit
Slide 11: Caffeine, Paracetamol & Sewage
Caffeine, Paracetamol & Sewage 11 ▪The results of lateral flow tests for caffeine and paracetamol (human derived by-products) should link to established standards for water quality ▪QR code and smartphone technology could stimulate citizen testing Bioventix
Slide 12: Bioventix Strategy
12 Bioventix Strategy ▪ Continue with the Alzheimer’s disease biomarker and assay development work with the University of Gothenburg ▪ Seek additional neurological diagnostic biomarkers that suit our antibody technology and identify partner collaborators (ie similar to Tau & University of Gothenburg
Slide 13: Bioventix Lab, Farnham
13 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Staff continuity has remained high with no recent departures or retirements Bioventix
Slide 14: Bioventix Directors
14 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 15: Significant Shareholders
15 Significant Shareholders Institution Shares % (1000s) Gresham House 628 12.0 Liontrust 571 11.0 Total shares = 5,219,656 (Mar 2025) Sanford DeLand 498 9.5 Hargreaves Lansdown Stockbrokers 363 7.0 Peter Harrison 297 5.7 ▪From permissions, other Schroder Investment Management 285 5.5 available data
Slide 16: Conclusions and Outlook
16 Conclusions and Outlook ▪ Sales of our vitamin D antibody and other core SMAs have been steady and in line with expectations ▪ Troponin revenues have been disappointing. A new prognostic application for “at risk” heart patients has not yet stimulated sales ▪ Manufacture and commercialisation of T